Åke Berglund

The effect of BRAF^V600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer: A post-hoc exploratory analysis of the randomized NORDIC9-study

Liposits, Gabor; Winther, Stine B.; Ryg, Jesper; Skuladottir, Halla et al.

Part of Journal of Geriatric Oncology, 2024

• DOI for The effect of BRAF^V600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer: A post-hoc exploratory analysis of the randomized NORDIC9-study
• Download full text (pdf) of The effect of BRAF^V600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer: A post-hoc exploratory analysis of the randomized NORDIC9-study

Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study

Liposits, Gabor; Ryg, Jesper; Skuladottir, Halla; Winther, Stine B. et al.

Part of Journal of Geriatric Oncology, 2023

• DOI for Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study
• Download full text (pdf) of Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study

Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery

Dijkstra, Esmee A.; Nilsson, Per J.; Hospers, Geke A. P.; Bahadoer, Renu R. et al.

Part of Annals of Surgery, 2023

• DOI for Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery

Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer

Falk, Philip; Severin, Mira; Berglund, Åke; Guren, Marianne G. et al.

Part of Cancer Treatment and Research Communications, 2022

• DOI for Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer
• Download full text (pdf) of Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer

The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study

Liposits, Gabor; Skuladottir, Halla; Ryg, Jesper; Winther, Stine Braendegaard et al.

Part of Journal of Clinical Medicine, 2022

• DOI for The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study
• Download full text (pdf) of The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study

The effect of BRAF^V600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer: A post-hoc exploratory analysis of the randomized NORDIC9-study

Liposits, Gabor; Winther, Stine B.; Ryg, Jesper; Skuladottir, Halla et al.

Part of Journal of Geriatric Oncology, 2024

• DOI for The effect of BRAF^V600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer: A post-hoc exploratory analysis of the randomized NORDIC9-study
• Download full text (pdf) of The effect of BRAF^V600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer: A post-hoc exploratory analysis of the randomized NORDIC9-study

Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study

Liposits, Gabor; Ryg, Jesper; Skuladottir, Halla; Winther, Stine B. et al.

Part of Journal of Geriatric Oncology, 2023

• DOI for Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study
• Download full text (pdf) of Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study

Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery

Dijkstra, Esmee A.; Nilsson, Per J.; Hospers, Geke A. P.; Bahadoer, Renu R. et al.

Part of Annals of Surgery, 2023

• DOI for Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery

Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer

Falk, Philip; Severin, Mira; Berglund, Åke; Guren, Marianne G. et al.

Part of Cancer Treatment and Research Communications, 2022

• DOI for Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer
• Download full text (pdf) of Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer

The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study

Liposits, Gabor; Skuladottir, Halla; Ryg, Jesper; Winther, Stine Braendegaard et al.

Part of Journal of Clinical Medicine, 2022

• DOI for The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study
• Download full text (pdf) of The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study

Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy: The Randomized NORDIC9-Study

Liposits, Gabor; Eshoj, Henrik Rode; Möller, Sören; Braendegaard Winther, Stine et al.

Part of Cancers, 2021

• DOI for Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy: The Randomized NORDIC9-Study
• Download full text (pdf) of Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy: The Randomized NORDIC9-Study

Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full- dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial

Whither, Stine Braendegaard; Liposits, Gabor; Skuladottir, Haifa; Hofsli, Eva et al.

Part of The Lancet Gastroenterology & Hepatology, p. 376-388, 2019

• DOI for Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full- dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9

Winther, Stine Braendegaard; Österlund, Pia; Berglund, Åke; Glimelius, Bengt et al.

Part of BMC Cancer, 2017

• DOI for Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9
• Download full text (pdf) of Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9

Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial

Erlandsson, Johan; Holm, Torbjörn; Pettersson, David; Berglund, Åke et al.

Part of The Lancet Oncology, p. 336-346, 2017

• DOI for Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial

A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial

Hagman, H.; Frodin, J. -E; Berglund, Åke; Sundberg, J. et al.

Part of Annals of Oncology, p. 140-147, 2016

• DOI for A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial

NORDIC9: A randomized phase II trial exploring treatment of older patients with metastatic colorectal cancer (mCRC) by comparing full dose monotherapy (S-1 followed by irinotecan) with reduced combination regimen (S-1/oxaliplatin followed by S-1/irinotecan)

Winther, S. B.; Osterlund, P.; Berglund, Åke; Glimelius, Bengt et al.

Part of Annals of Oncology, 2016

• DOI for NORDIC9: A randomized phase II trial exploring treatment of older patients with metastatic colorectal cancer (mCRC) by comparing full dose monotherapy (S-1 followed by irinotecan) with reduced combination regimen (S-1/oxaliplatin followed by S-1/irinotecan)

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Berglund, Åke; Ullen, Anders; Lisyanskaya, Alla; Orlov, Sergey et al.

Part of Investigational new drugs, p. 1232-1241, 2015

• DOI for First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial

Breugom, A. J.; van Gijn, W.; Muller, E. W.; Berglund, Åke et al.

Part of Annals of Oncology, p. 696-701, 2015

• DOI for Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial

A randomized pilot study with daily walking during adjuvant chemotherapy for patients with breast and colorectal cancer

Backman, Malin; Wengstrom, Yvonne; Johansson, Birgitta; Sköldengen, Ida et al.

Part of Acta Oncologica, p. 510-520, 2014

• DOI for A randomized pilot study with daily walking during adjuvant chemotherapy for patients with breast and colorectal cancer

The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab

Berglund, Åke; Willen, Linda; Grodeberg, Lina; Skattum, Lillemor et al.

Part of Acta Oncologica, p. 1212-1220, 2014

• DOI for The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab

A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial

Johnsson, A.; Hagman, H.; Frodin, J. -E; Berglund, Åke et al.

Part of Annals of Oncology, p. 2335-2341, 2013

• DOI for A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial

Daily walking during adjuvant chemotherapy for patients with breast and colorectal cancer - a randomized pilot study

Malin, M. Backman; Yvonne, Y. Wengstrom; Johansson, Birgitta; Skoldengen, Ida et al.

Part of European Journal of Cancer, 2013

Health-related quality of life in patients with metastatic colorectal cancer receiving palliative combination chemotherapy

Byström, Per; Johansson, Birgitta; Berglund, Åke; Sorbye, H et al.

2012

Evaluation of predictive markers for patients with advanced colorectal cancer

Byström, Per; Berglund, Åke; Nygren, Peter; Wernroth, Lisa et al.

Part of Acta Oncologica, p. 849-859, 2012

• DOI for Evaluation of predictive markers for patients with advanced colorectal cancer

The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy

Suzuki, C; Blomqvist, L; Sundin, Anders; Jacobsson, H et al.

Part of Annals of Oncology, p. 948-954, 2012

• DOI for The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy

Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer: Long-term results from a phase III study

Brændengen, Morten; Tveit, Kjell M; Hjermstad, Marianne J; Johansson, Hemming et al.

Part of European Journal of Cancer, p. 813-819, 2012

• DOI for Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer: Long-term results from a phase III study

Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer

Frederiksen, C.; Qvortrup, C.; Christensen, I. J.; Glimelius, Bengt et al.

Part of Annals of Oncology, p. 369-375, 2011

• DOI for Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer

Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer

Glimelius, Bengt; Garmo, Hans; Berglund, Åke; Fredriksson, L. A. et al.

Part of The Pharmacogenomics Journal, p. 61-71, 2011

• DOI for Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer

Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: Results from a randomized phase III study

Braendengen, Morten; Tveit, Kjell Magne; Bruheim, Kjersti; Cvancarova, Milada et al.

Part of International Journal of Radiation Oncology, Biology, Physics, p. 1017-1024, 2011

• DOI for Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: Results from a randomized phase III study

Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study

Glimelius, Bengt; Spindler, K. L.; Frödin, J-E.; Berglund, Åke et al.

Part of Annals of Oncology, p. 1127-1128, 2010

• DOI for Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study

High Plasma TIMP-1 and Serum CEA Levels during Combination Chemotherapy for Metastatic Colorectal Cancer Are Significantly Associated with Poor Outcome

Aldulaymi, Bahir; Byström, Per; Berglund, Åke; Christensen, Ib J. et al.

Part of Oncology, p. 144-149, 2010

• DOI for High Plasma TIMP-1 and Serum CEA Levels during Combination Chemotherapy for Metastatic Colorectal Cancer Are Significantly Associated with Poor Outcome

An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer

Berglund, Åke; Byström, Per; Johansson, Birgitta; Nygren, Peter et al.

Part of Medical Oncology, p. 65-72, 2010

• DOI for An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer

Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data

von Heideman, Anne; Berglund, Åke; Larsson, Rolf; Nygren, Peter

Part of Cancer Chemotherapy and Pharmacology, p. 1165-1172, 2010

• DOI for Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data

Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial

Gubanski, Michael; Johnsson, Anders; Fernebro, Eva; Kadar, Lianna et al.

Part of Gastric Cancer, p. 155-161, 2010

• DOI for Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial

A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer

Glimelius, Bengt; Lahn, M.; Gawande, S.; Cleverly, A. et al.

Part of Annals of Oncology, p. 1020-1026, 2010

• DOI for A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer

An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer

Byström, P.; Berglund, Åke; Nygren, Peter; Wernroth, Mona-Lisa et al.

Part of Oncology Reports, p. 1645-1652, 2010

• DOI for An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer

Serum vitamin B12 and folate status among patients with chemotherapy treatment for advanced colorectal cancer

Byström, Per; Björkegren, Karin; Larsson, Anders; Johansson, Linda et al.

Part of Upsala Journal of Medical Sciences, p. 160-164, 2009

• DOI for Serum vitamin B12 and folate status among patients with chemotherapy treatment for advanced colorectal cancer

Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: The CORGI-L study

Gunnlaugsson, Adalsteinn; Anderson, Harald; Fernebro, Eva; Kjellén, Elisabeth et al.

Part of European Journal of Cancer, p. 807-813, 2009

• DOI for Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: The CORGI-L study

A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer

Glimelius, Bengt; Sørbye, H; Balteskard, L; Byström, P et al.

Part of Annals of Oncology, p. 909-914, 2008

• DOI for A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer

Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil

Qvortrup, Camilla; Yilmaz, M.; Ogreid, D.; Berglund, Åke et al.

Part of Annals of Oncology, p. 1154-9, 2008

• DOI for Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil

Short-course preoperative radiotherapy with delayed surgery in rectal cancer: a retrospective study

Radu, Calin; Berglund, Åke; Påhlman, Lars; Glimelius, Bengt

Part of Radiotherapy and Oncology, p. 343-9, 2008

• DOI for Short-course preoperative radiotherapy with delayed surgery in rectal cancer: a retrospective study

Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer

Braendengen, Morten; Tveit, Kjell M.; Berglund, Åke; Birkemeyer, Elke et al.

Part of Journal of Clinical Oncology, p. 3687-3694, 2008

• DOI for Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer

Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III?

Berglund, Åke; Cedermark, B; Glimelius, Bengt

Part of Annals of Oncology, p. 400-402, 2008

• DOI for Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III?

Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

Sørbye, Halfdan; Berglund, Åke; Tveit, Kjell Magne; Ogreid, Dagfinn et al.

Part of Acta Oncologica, p. 982-988, 2007

• DOI for Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid

Sørensen, Nanna M; Byström, Per; Christensen, Ib J; Berglund, Åke et al.

Part of Clinical Cancer Research, p. 4117-4122, 2007

• DOI for TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid

[Limit investigation in cancer of unknown primary site]

Berglund, Ake; Nygren, Peter; Hagberg, Hans; Pahlman, Lars et al.

Part of Lakartidningen, p. 2946-8, 2950, 2005

Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study.

Mahteme, H; Hansson, J; Berglund, Åke; Påhlman, Lars et al.

Part of Br J Cancer, p. 403-7, 2004

Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer.

Sörbye, Halfdan; Glimelius, Bengt; Berglund, Ake; Fokstuen, Tone et al.

Part of J Clin Oncol, p. 31-8, 2004

Phase I study of UFT plus leucovorin with radiotherapy in patients with inextirpable non-rectal gastrointestinal cancer.

Byström, P; Frödin, J-E; Berglund, A; Wilking, Nils et al.

Part of Radiother Oncol, p. 171-5, 2004